TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10588212

Group type: EXPERIMENTAL
Intervention: High endotoxin levels (beyond 50 pg/ml)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: High endotoxin levels
Number of subjects: 516

Group type: COMPARATOR
Intervention: Low endotoxin levels in smokers
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: High endotoxin levels in smokers
Number of subjects: 516
Study: 8954302

Group type: EXPERIMENTAL
Intervention: DNA analysis for expanded trinucleotide (CAG) repeat sequence in the IT15 gene
Number of subjects: 27
Study: 1772813

Group type: EXPERIMENTAL
Intervention: Tourniquet application (varied by width and inflation pressure)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tourniquet application (maintenance of inflation)
Number of subjects: 12
Study: 7047002

Group type: EXPERIMENTAL
Intervention: Prednisone plus 'triple‐treatment' (vitamin D2 45000 iu twice weekly, sodium fluoride 50 mg and calcium phosphate 4.5 g daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Prednisone only (Control)
Number of subjects: 31
Study: 31868983

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 2 L/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 4 L/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 6 L/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 8 L/min
Number of subjects: 16
Study: 29924955

Group type: EXPERIMENTAL
Intervention: Cisplatin plus sodium thiosulfate (20 g/m² intravenously over 15 minutes, 6 hours after cisplatin)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Cisplatin alone (80 mg/m² over 6 hours)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Cisplatin plus sodium thiosulfate
Number of subjects: 109

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 109
Study: 26971473

Group type: EXPERIMENTAL
Intervention: Active E‐NFT
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham E‐NFT
Number of subjects: 25
Study: 24525469

Group type: EXPERIMENTAL
Intervention: RPV/FTC/TDF
Number of subjects: 786

Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 786
Study: 22335299

Group type: EXPERIMENTAL
Intervention: Ketac Nano (KN)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fuji Filling LC (FF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fuji II LC (FII)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fuji II LC without light cure (FII woLC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fuji Filling LC without light cure (FF woLC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketac Nano without light cure (KN woLC)
Number of subjects: 60
Study: 21351399

Group type: EXPERIMENTAL
Intervention: Postoperative coiling of the AAA sac (Group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No coiling of the AAA sac (Group B)
Number of subjects: 86
Study: 18051002

Group type: EXPERIMENTAL
Intervention: Resin adhesive (Seal & Protect) applied to coated teeth
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (uncoated teeth)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Resin adhesive (Seal & Protect)
Number of subjects: 19
Study: 16289797

Group type: EXPERIMENTAL
Intervention: Minimal Intervention Strategy (MIS)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 314
Study: 12243243

Group type: EXPERIMENTAL
Intervention: Hylan B gel dressing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no gel dressing)
Number of subjects: 20
Study: 10576139

Group type: EXPERIMENTAL
Intervention: Bacterial meningitis group (n=18)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 18
Study: 8549224

Group type: COMPARATOR
Intervention: Subcutaneous heparin (SCH) 5,000 U every 12 hours
Number of subjects: 2551

Group type: EXPERIMENTAL
Intervention: Combined use of pneumatic compression stockings (PCS) and subcutaneous heparin (SCH)
Number of subjects: 2551
Study: 1986565

Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin I converting enzyme inhibitor)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 6134626

Group type: EXPERIMENTAL
Intervention: Activated charcoal suspension (50 g charcoal)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Syrup of ipecac
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water (300 ml)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Activated charcoal vs. ipecac
Number of subjects: 6
Study: 31201785

Group type: EXPERIMENTAL
Intervention: Azithromycin treatment for 28 days
Number of subjects: 40
Study: 30053620

Group type: EXPERIMENTAL
Intervention: Flow diversion (FD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical group (bypass)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flow diversion (FD) and Bypass surgery
Number of subjects: 40
Study: 27062084

Group type: EXPERIMENTAL
Intervention: Baby-friendly Initiative (BFI) in community health services
Number of subjects: 3948

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 3948
Study: 25065668

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20mg/day) followed by Lapatinib (1500mg/day) after 28 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lapatinib (1500mg/day) followed by Tamoxifen (20mg/day) after 14 days
Number of subjects: 25
Study: 22301368

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents with biodegradable polymer
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 1161
Study: 21058129

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 52
Study: 16761216

Group type: EXPERIMENTAL
Intervention: Resistance training program (12 weeks, 2 sessions per week, increasing to 4 sessions per week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study: 15896352

Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 12169931

Group type: EXPERIMENTAL
Intervention: TBOPP program
Number of subjects: 132

Group type: COMPARATOR
Intervention: noTBOPP group
Number of subjects: 132
Study: 11338314

Group type: EXPERIMENTAL
Intervention: Drug treatment for hypertension
Number of subjects: 2301

Group type: COMPARATOR
Intervention: Untreated candidates for drug treatment
Number of subjects: 2301
Study: 9544892

Group type: EXPERIMENTAL
Intervention: Inhaled steroids (budesonide or beclomethasone)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control subjects (non-steroid treated)
Number of subjects: 56
Study: 8290193

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (60 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intravenous fentanyl (100 micrograms at induction, 25 micrograms boluses after 45 and 90 minutes)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oral piroxicam (40 mg)
Number of subjects: 84
Study: 2691141

Group type: EXPERIMENTAL
Intervention: Diltiazem (short-term, 2 weeks)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Diltiazem (long-term, 12-52 months)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Diltiazem (in patients with cardiac failure)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 576

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 576
Study: 46049

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 68
Study: 6985729

Group type: EXPERIMENTAL
Intervention: 5FU + Mito C (20 mg/m2 IV bolus every 8 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 5FU + MeCCNU (150 mg/m2 orally every 8 weeks)
Number of subjects: 57
Study: 30665229

Group type: EXPERIMENTAL
Intervention: Short-foot exercise (SFE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Proprioceptive sensory exercise (PSE)
Number of subjects: 30
Study: 30203746

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of zoledronic acid combined with oral medication of cinobufagin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous infusion of zoledronic acid
Number of subjects: 120
Study: 26537183

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24976202

Group type: EXPERIMENTAL
Intervention: Albendazole and antiepileptics
Number of subjects: 123

Group type: COMPARATOR
Intervention: Antiepileptics only (Control)
Number of subjects: 123
Study: 22585886

Group type: EXPERIMENTAL
Intervention: EHR use
Number of subjects: 798

Group type: COMPARATOR
Intervention: Non-EHR use (Control)
Number of subjects: 798
Study: 20814335

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Quercetin (2000 mg)
Number of subjects: 57
Study: 17654600

Group type: EXPERIMENTAL
Intervention: IFN beta-1a
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: IFN beta-1a plus ribavirin
Number of subjects: 257
Study: 16038841

Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT) for 20 min, once a day, 5 days a week, over a period of 3 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT) + 1000 mg naproxen (NSAID)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 1000 mg naproxen (NSAID)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT)
Number of subjects: 61
Study: 11815495

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1439

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1439

Group type: EXPERIMENTAL
Intervention: Afternoon and evening plasma glucose measurements
Number of subjects: 1439
Study: 9873161

Group type: EXPERIMENTAL
Intervention: Cobalt-55 (55Co) positron emission tomography (PET) tracer
Number of subjects: 0
Study: 7853167

Group type: EXPERIMENTAL
Intervention: OPC-31260 (3, 15, 30, 60, 100, and 200 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: OPC-31260 (60-200 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: OPC-31260 (100 and 200 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: OPC-31260 (200 mg)
Number of subjects: 18
Study: 1955232

Group type: EXPERIMENTAL
Intervention: levamisole 5 mg/kg body weight on 3 consecutive days every 2 weeks for a period up to 5 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 6816006

Group type: EXPERIMENTAL
Intervention: Penicillin V 25 or 50 mg/kg body weight twice a day for 5 days
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Penicillin V 25 mg/kg body weight twice a day for 10 days
Number of subjects: 297
Study: 31818723

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (N = 35)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) (N = 30)
Number of subjects: 65
Study: 30634007

Group type: EXPERIMENTAL
Intervention: Variability of attentional bias (AB) for food stimuli
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Variability of reaction time (RT) on filler trials
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mean AB score
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dwell time variability
Number of subjects: 3
Study: 30385543

Group type: EXPERIMENTAL
Intervention: Daily work breaks in a hospital-integrated garden
Number of subjects: 29

Group type: COMPARATOR
Intervention: Indoor-only breaks
Number of subjects: 29
Study: 26815178

Group type: EXPERIMENTAL
Intervention: Graded exercise treadmill test to exhaustion
Number of subjects: 59
Study: 25133177

Group type: EXPERIMENTAL
Intervention: Prilocaine + 8.4% NaHCO3 (Group PN)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Prilocaine (Group P)
Number of subjects: 64
Study: 22297687

Group type: EXPERIMENTAL
Intervention: Simple CDS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Multifaceted CDS
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no CDS)
Number of subjects: 41
Study: 19614689

Group type: EXPERIMENTAL
Intervention: PGI(2) (10 ng kg(‐1) min(‐1) infusion over 25 min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PGI(2)
Number of subjects: 12
Study: 17427824

Group type: EXPERIMENTAL
Intervention: Excite bonding agent with light activation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: One‐Step bonding agent with light activation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Excite DSC bonding agent with light activation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dual‐cured resin composite (Luxacore Dualcure)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Self‐cured resin composite (Luxacore)
Number of subjects: 120
Study: 15752393

Group type: EXPERIMENTAL
Intervention: Propofol + remifentanil (1 microg kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol + fentanyl (2 microg kg(‐1))
Number of subjects: 60
Study: 12442921

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin and methotrexate
Number of subjects: 153

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 153
Study: 10225151

Group type: EXPERIMENTAL
Intervention: 0.4 mm diameter Teflon platinum piston
Number of subjects: 200

Group type: COMPARATOR
Intervention: 0.6 mm diameter Teflon piston
Number of subjects: 200
Study: 7675979

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginkgold (a type of Ginkgo biloba extract)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 0
Study: 2137644

Group type: EXPERIMENTAL
Intervention: Chondroprotective agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment of OA of the knee
Number of subjects: 0
Study: 382152

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg t.d.s.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30116112

Group type: EXPERIMENTAL
Intervention: Conventional compression garment (18-21 mmHg) applied to one calf for 60 hours after exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-compressed calf
Number of subjects: 15
Study: 26669417

Group type: EXPERIMENTAL
Intervention: Music therapy (20 minutes)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (rest for 20 minutes)
Number of subjects: 64
Study: 24906585

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (40 min, twice per week for 4 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (one-time treatment)
Number of subjects: 25
Study: 22295870

Group type: EXPERIMENTAL
Intervention: ProSeal™ laryngeal mask airway (PLMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classic™ laryngeal mask airway (cLMA)
Number of subjects: 60
Study: 20307214

Group type: EXPERIMENTAL
Intervention: Tacrolimus ophthalmic suspension 0.1%
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 18547415

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulphadoxine‐Pyrimethamine (AQ+SP)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Artesunate + Amodiaquine (AS+AQ)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Artemether‐Lumefantrine (AL)
Number of subjects: 601
Study: 16038456

Group type: EXPERIMENTAL
Intervention: Vascularized bone graft-RBX (group A)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vascularized bone graft (group B)
Number of subjects: 27

Group type: COMPARATOR
Intervention: RBX (group C)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 27
Study: 12373468

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 106
Study: 10365743

Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Picotamide, Indobufen, Low molecular weight heparins, Sulodexide, Defibrotide
Number of subjects: 0
Study: 7771913

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride, 1.0 mg/kg per day
Number of subjects: 23
Study: 2125153

Group type: EXPERIMENTAL
Intervention: Rifampicin, streptomycin, isoniazid and pyrazinamide daily for 3 months (R3)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: The same regimen as R3 followed by streptomycin, isoniazid and pyrazinamide twice-weekly for a further period of 2 months (R5)
Number of subjects: 325

Group type: COMPARATOR
Intervention: The same as R5 but without rifampicin (Z5)
Number of subjects: 325
Study: 7446621

Group type: EXPERIMENTAL
Intervention: Ovulation Method (OM)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Symptothermal Method (STM)
Number of subjects: 566
Study: 31516033

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF (800/150/200/10 mg)
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Boosted darunavir plus emtricitabine/tenofovir-disoproxil-fumarate
Number of subjects: 1754
Study: 31647468

Group type: EXPERIMENTAL
Intervention: Supportive antismoking ads
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Graphic antismoking ads
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Price promotions
Number of subjects: 1970
Study: 28645997

Group type: EXPERIMENTAL
Intervention: Antibiotic-containing elastomeric infusion devices
Number of subjects: 115
Study: 26165375

Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: High glycemic load (GL) diet
Number of subjects: 19
Study: 23225237

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg daily plus advice for exercise and lifestyle modification
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lifestyle modification alone
Number of subjects: 99

Group type: COMPARATOR
Intervention: Healthy subjects (normoglycemic)
Number of subjects: 99
Study: 21511783

Group type: EXPERIMENTAL
Intervention: On-site outreach education in intervention clinics
Number of subjects: 150

Group type: COMPARATOR
Intervention: No outreach education in control clinics
Number of subjects: 150
Study: 19497653

Group type: EXPERIMENTAL
Intervention: Cervitec (chlorhexidine-thymol varnish)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 16510610

Group type: EXPERIMENTAL
Intervention: Higher baseline HbA1c levels
Number of subjects: 27110

Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 27110
Study: 15514506

Group type: EXPERIMENTAL
Intervention: 30 min of running at 50% VO2max
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 min of low-frequency EMS on the lower limb extensor muscles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 0
Study: 11101186

Group type: EXPERIMENTAL
Intervention: Dry powder fluticasone propionate 200 microg once daily (QD)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Dry powder fluticasone propionate 100 microg twice daily (BID)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 9298513

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg daily, PO)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 7914737

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microgram/kg i.v. (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo i.v. (n = 15)
Number of subjects: 30
Study: 3051880

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (100 mg daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31264412

Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 0
Study: 29378106

Group type: EXPERIMENTAL
Intervention: Group preventive consultation in the School of a balanced nutrition
Number of subjects: 242
Study: 23246022

Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Number of subjects: 1491

Group type: COMPARATOR
Intervention: Fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 1491
Study: 20622656

Group type: EXPERIMENTAL
Intervention: ONS (oral nutritional supplement)
Number of subjects: 40
Study: 18783301

Group type: EXPERIMENTAL
Intervention: Combination therapy with ABT-335 135 mg/day and rosuvastatin (10 mg/day and 20 mg/day)
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Combination therapy with ABT-335 135 mg/day and atorvastatin (20 mg/day and 40 mg/day)
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Combination therapy with ABT-335 135 mg/day and simvastatin (20 mg/day and 40 mg/day)
Number of subjects: 2400

Group type: COMPARATOR
Intervention: ABT-335 monotherapy
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Statin monotherapy (rosuvastatin, atorvastatin, simvastatin)
Number of subjects: 2400
Study: 16635593

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (plant‐based, low‐fat diet; exercise; stress management) for 1 year
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for patients with DM
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for patients without DM
Number of subjects: 440
Study: 14616319

Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.5, 1.0 and 1.5 MAC in 30% oxygen
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.0 MAC over a 90‐min period
Number of subjects: 26
Study: 10948782

Group type: EXPERIMENTAL
Intervention: DDD pacemaker in activated mode (DDD with optimized short AV delay)
Number of subjects: 83

Group type: COMPARATOR
Intervention: AAI pacemaker in inactivated mode
Number of subjects: 83
Study: 8919902

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5% at a dose of 0.5-1.0 mg/kg for spinal anesthesia
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5%
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with hyperbaric bupivacaine 0.5%
Number of subjects: 5
Study: 1748115

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prophylaxis
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (no antibiotic prophylaxis)
Number of subjects: 54